Why Summit Therapeutics Stock Is Jumping Today

Shares of Summit Therapeutics (SMMT 15.95%) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating for the stock with a 12-month price target of $44. Kapoor's target price reflects an upside potential for Summit of over 100%. Other Wall Street analysts are also bullish about the biotech stock, although not to the same extent. The average price target for Summit is roughly 52% above the current share price. Undersc ...